Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...
The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is ...
Flagship Pioneering-founded Generate Biomedicines is tacking on a gigantic $273 million in series C funds, though the haul didn't reach the heights of the biotech’s previous $370 million raise back in ...
Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis. The wide-ranging deal, worth up to $1 billion, ...
Generate Biomedicines, which uses artificial intelligence for protein design, recently opened a cryo-electron microscopy (cryo-EM) laboratory in Andover, Massachusetts, that it says will accelerate ...
Generate Biomedicines is setting out to “program” medicine by almost instantaneously creating models of new proteins. Launched out of life sciences venture firm Flagship Pioneering, it raised a large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results